Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

670 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether erlotinib is more effective than a placebo in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works compared to a placebo in treating patients with stage III or stage IV non-small cell lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Compare survival of patients with stage IIIB or IV non-small cell lung cancer that is not suitable for first-line chemotherapy treated with erlotinib vs placebo.

Secondary

* Compare progression-free survival and response rate.
* Compare toxicity.
* Compare the quality of life.
* Compare cost-effectiveness.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral erlotinib once daily for up to 24 months.
* Arm II: Patients receive oral placebo once daily for up to 24 months. Quality of life is assessed periodically.

After completion of study treatment, patients are followed periodically for survival.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 664 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erlotinib

Tarceva (OSI-774, erlotinib) PO 150mg daily

Group Type EXPERIMENTAL

erlotinib hydrochloride

Intervention Type DRUG

Tarceva (OSI-774, erlotinib) PO 150 mg daily

Matched placebo

Matched placebo PO daily

Group Type PLACEBO_COMPARATOR

Matched placebo

Intervention Type DRUG

Matched placebo PO daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erlotinib hydrochloride

Tarceva (OSI-774, erlotinib) PO 150 mg daily

Intervention Type DRUG

Matched placebo

Matched placebo PO daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OSI-774 Tarceva

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer

* Advanced disease (stage IIIB or IV)
* Diagnosis within 62 days prior to randomization
* Not suitable for first-line chemotherapy, as defined by the following criteria\*:

* ECOG performance status 2-3
* ECOG performance status 0-1 AND creatinine clearance \< 60 mL/min
* NOTE: \*These criteria do not imply that all such patients are unsuitable for chemotherapy; patients are considered unsuitable on a case by case basis
* No symptomatic brain metastases

PATIENT CHARACTERISTICS:

* Estimated life expectancy of at least 8 weeks
* Able to take oral medication
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No severe uncontrolled infection
* No unstable angina
* No myocardial infarction within the past month
* No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
* No acute renal failure
* Bilirubin \< 2 times upper limit of normal (ULN)
* Transaminases \< 2 times ULN (5 times ULN if liver metastases are present)
* Creatinine \< 5 times ULN
* No evidence of other significant laboratory finding or uncontrolled medical illness that would interfere with study treatment or results comparison or render the patient at high risk from treatment complications
* No other prior or current malignant disease likely to interfere with study treatment or comparisons

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy
* No prior biological anticancer therapy (e.g., gefitinib, thalidomide, or cetuximab)
* No prior palliative radiotherapy

* Prior palliative radiotherapy to bone metastases allowed within the past 2 weeks
* No concurrent cyclooxygenase-2 inhibitors

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Siow M Lee, MD, PhD, FRCP

Role: STUDY_CHAIR

University College London Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

London Lung Cancer Group

London, England, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom